Types of Erythropoietin-Stimulating Agents and Mortality among Patients Undergoing Hemodialysis.
Aged
Anemia
/ drug therapy
Cause of Death
Cohort Studies
Darbepoetin alfa
/ adverse effects
Dose-Response Relationship, Drug
Drug Administration Schedule
Epoetin Alfa
/ adverse effects
Female
Humans
Japan
Kidney Failure, Chronic
/ diagnosis
Male
Middle Aged
Multivariate Analysis
Prognosis
Proportional Hazards Models
Registries
Renal Dialysis
/ adverse effects
Retrospective Studies
Risk Assessment
Survival Analysis
Treatment Outcome
erythropoietin-stimulating agents
hemodialysis
mortality
Journal
Journal of the American Society of Nephrology : JASN
ISSN: 1533-3450
Titre abrégé: J Am Soc Nephrol
Pays: United States
ID NLM: 9013836
Informations de publication
Date de publication:
06 2019
06 2019
Historique:
received:
12
10
2018
accepted:
01
03
2019
pubmed:
25
4
2019
medline:
26
2
2020
entrez:
25
4
2019
Statut:
ppublish
Résumé
Despite the widespread use of erythropoietin-stimulating agents (ESAs) to treat anemia in patients undergoing hemodialysis, the relative mortality risks associated with use of different types of ESAs are unknown. To compare the mortality risk associated with use of short-acting ESAs versus long-acting ESAs, we conducted a nationwide cohort study of 194,698 hemodialysis patients in Japan who received either a short-acting (epoetin During the 2-year follow-up period, 31,557 deaths occurred. In a multivariable Cox model, long-acting ESA users had a 13% higher rate of deaths compared with short-acting ESA users, a significant difference ( Among patients undergoing hemodialysis, use of long-acting ESAs might be associated with a higher risk of death than use of short-acting ESAs.
Sections du résumé
BACKGROUND
Despite the widespread use of erythropoietin-stimulating agents (ESAs) to treat anemia in patients undergoing hemodialysis, the relative mortality risks associated with use of different types of ESAs are unknown.
METHODS
To compare the mortality risk associated with use of short-acting ESAs versus long-acting ESAs, we conducted a nationwide cohort study of 194,698 hemodialysis patients in Japan who received either a short-acting (epoetin
RESULTS
During the 2-year follow-up period, 31,557 deaths occurred. In a multivariable Cox model, long-acting ESA users had a 13% higher rate of deaths compared with short-acting ESA users, a significant difference (
CONCLUSIONS
Among patients undergoing hemodialysis, use of long-acting ESAs might be associated with a higher risk of death than use of short-acting ESAs.
Identifiants
pubmed: 31015255
pii: ASN.2018101007
doi: 10.1681/ASN.2018101007
pmc: PMC6551773
doi:
Substances chimiques
Darbepoetin alfa
15UQ94PT4P
Epoetin Alfa
64FS3BFH5W
Types de publication
Comparative Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1037-1048Commentaires et corrections
Type : CommentIn
Type : CommentIn
Type : CommentIn
Type : CommentIn
Informations de copyright
Copyright © 2019 by the American Society of Nephrology.
Références
Ann Intern Med. 1989 Dec 15;111(12):992-1000
pubmed: 2688507
Kidney Int. 2008 Sep;74(6):791-8
pubmed: 18596733
Blood. 2010 Feb 18;115(7):1453-60
pubmed: 20008786
J Am Soc Nephrol. 1999 Jun;10(6):1309-16
pubmed: 10361870
J Am Soc Nephrol. 2014 Sep;25(9):2003-15
pubmed: 24676641
Blood. 1999 Apr 15;93(8):2627-36
pubmed: 10194442
Am J Epidemiol. 2009 Feb 1;169(3):273-84
pubmed: 19033525
Am J Kidney Dis. 2015 Jul;66(1):106-13
pubmed: 25943715
Kidney Int. 1990 Sep;38(3):480-6
pubmed: 2232491
Front Immunol. 2014 Nov 11;5:563
pubmed: 25426117
Stat Med. 2016 May 20;35(11):1763-73
pubmed: 26694758
N Engl J Med. 2009 Nov 19;361(21):2019-32
pubmed: 19880844
Proc Natl Acad Sci U S A. 1994 Apr 26;91(9):3974-8
pubmed: 8171022
CMAJ. 2007 Feb 27;176(5):627-32
pubmed: 17325327
JAMA. 1990 Feb 9;263(6):825-30
pubmed: 2404150
N Engl J Med. 1987 Jan 8;316(2):73-8
pubmed: 3537801
N Engl J Med. 2006 Nov 16;355(20):2071-84
pubmed: 17108342
J Am Soc Nephrol. 1999 Mar;10(3):610-9
pubmed: 10073612
Kidney Int. 1991 Jan;39(1):155-63
pubmed: 2002629
Kidney Int. 1996 Aug;50(2):481-8
pubmed: 8840276
Lancet. 2009 May 2;373(9674):1532-42
pubmed: 19410717
Proc Natl Acad Sci U S A. 1990 Aug;87(15):5978-82
pubmed: 2165612
Cochrane Database Syst Rev. 2014 Dec 08;(12):CD010590
pubmed: 25486075
N Engl J Med. 2006 Nov 16;355(20):2085-98
pubmed: 17108343
Ther Apher Dial. 2008 Dec;12(6):514-25
pubmed: 19140852
Exp Hematol. 1987 Nov;15(10):1028-34
pubmed: 3499335
Am J Kidney Dis. 2015 Jul;66(1):69-74
pubmed: 25636816
Cancer Res. 2013 Nov 1;73(21):6393-400
pubmed: 24008319
N Engl J Med. 1998 Aug 27;339(9):584-90
pubmed: 9718377
J Clin Invest. 1987 Jan;79(1):286-9
pubmed: 3793927
Kidney Int. 1992 Sep;42(3):668-72
pubmed: 1405344
Nephrol Dial Transplant. 2009 Mar;24(3):963-72
pubmed: 19028748
Immunity. 2011 Jan 28;34(1):61-74
pubmed: 21256055
Ther Apher Dial. 2014 Dec;18(6):535-602
pubmed: 25523509